Exelixis (EXEL) stock analysis: 14x 2026E EPS vs. sector, cabozantinib growth, zanzalintinib upside, and FDA/Q4 catalysts.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results